Prognosis in patients with MDS or AML and bone marrow blasts between 10% and 30% is not associated with blast counts but depends on cytogenetic and molecular genetic characteristics.

  • Ulrike Bacher
  • W Kern
  • T Alpermann
  • S Schnittger
  • A Kohlmann
  • H-U Klein
  • M Dugas
  • C Haferlach
  • T Haferlach

Bibliografische Daten

OriginalspracheEnglisch
Aufsatznummer8
ISSN0887-6924
StatusVeröffentlicht - 2011
pubmed 21494258